COMMON STOCK PURCHASE WARRANTCommon Stock Purchase Warrant • May 21st, 2018 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after _______________ (the “Initial Exercise Date”) and on or prior to the Termination Date but not thereafter, to subscribe for and purchase from Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder), the “Warrant Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Cidara Therapeutics, Inc. PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • May 21st, 2018 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
SUBSCRIPTION AGREEMENTSubscription Agreement • May 21st, 2018 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Subscription Agreement (this “Agreement”) is dated as of May 21, 2018 (the “Effective Date”), among Cidara Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each a “Purchaser” and collectively the “Purchasers”).
